Biblio

Author Title Type [ Year(Asc)]
Filters: Author is Hur, Jin  [Clear All Filters]
2021
Park H, Kim D, Cho B, Byun J, Kim YSook, Ahn Y, Hur J, Oh Y-K, Kim J. In vivo therapeutic genome editing via CRISPR/Cas9 magnetoplexes for myocardial infarction. Biomaterials. 2021;281:121327.
2020
Ha M, Kim J, Park SMin, Hong CMi, Han M-E, Song P, Kang C-D, Lee D, Kim YHak, Hur J, et al. Prognostic Role of Zinc Finger Homeobox 4 in Ovarian Serous Cystadenocarcinoma. Genet Test Mol Biomarkers. 2020.
2019
Yang H-M, Kim J-Y, Cho H-J, Lee J-E, Jin S, Hur J, Kwon Y-W, Seong M-W, Choi E-K, Lee H-Y, et al. NFATc1+CD31+CD45- circulating multipotent stem cells derived from human endocardium and their therapeutic potential. Biomaterials. 2019;232:119674.
2016
Hur J, Baek SHee, Kim H-S. KAI1(CD82)-DARC(CD234) Axis in the Stem Cell Niche. Cell Cycle. 2016.
Kang J, Hur J, Kang J-A, Lee HSeung, Jung H, Choi J-I, Lee H, Kim YSook, Ahn Y, Kim H-S. Priming mobilized peripheral blood mononuclear cells with the 'Activated Platelet Supernatant' enhances the efficacy of cell therapy for myocardial infarction of rats. Cardiovasc Ther. 2016.
2015
Kang HJin, Kang WSeok, Hong MHwa, Choe N, Kook H, Jeong HChang, Kang J, Hur J, Jeong MHo, Kim YSook, et al. Involvement of miR-34c in high glucose-insulted mesenchymal stem cells leads to inefficient therapeutic effect on myocardial infarction. Cell Signal. 2015.
2014
Kang J, Hur J, Kang J-A, Yun J-Y, Choi J-I, Ko SBum, Lee C-S, Lee J, Han J-K, Kim HKyung, et al. Activated platelet supernatant can augment the angiogenic potential of human peripheral blood stem cells mobilized from bone marrow by G-CSF. J Mol Cell Cardiol. 2014.
2013
Lee SHun, Lee JHee, Yoo SYoung, Hur J, Kim H-S, Kwon SMo. Hypoxia Inhibits Cellular Senescence to Restore the Therapeutic Potential of Old Human Endothelial Progenitor Cells via the Hypoxia-Inducible Factor-1α-TWIST-p21 Axis. Arterioscler Thromb Vasc Biol. 2013.